| Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies BD Lehmann, JA Bauer, X Chen, ME Sanders, AB Chakravarthy, Y Shyr, ... The Journal of clinical investigation 121 (7), 2750-2767, 2011 | 6217 | 2011 |
| WAF1/CIP1 Is Induced in p53-mediated G1 Arrest and Apoptosis WS El-Deiry, JW Harper, PM O'Connor, VE Velculescu, CE Canman, ... Cancer research 54 (5), 1169-1174, 1994 | 3027 | 1994 |
| Definition of a consensus binding site for p53 WS El-Deiry, SE Kern, JA Pietenpol, KW Kinzler, B Vogelstein Nature genetics 1 (1), 45-49, 1992 | 2750 | 1992 |
| Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 JD Oliner, JA Pietenpol, S Thiagalingam, J Gyuris, KW Kinzler, ... Nature 362 (6423), 857-860, 1993 | 1980 | 1993 |
| Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection BD Lehmann, B Jovanović, XI Chen, MV Estrada, KN Johnson, Y Shyr, ... PloS one 11 (6), e0157368, 2016 | 1466 | 2016 |
| TGF-β stimulation and inhibition of cell proliferation: new mechanistic insights HL Moses, EY Yang, JA Pietenpol Cell 63 (2), 245-247, 1990 | 1318 | 1990 |
| Oncogenic forms of p53 inhibit p53-regulated gene expression SE Kern, JA Pietenpol, S Thiagalingam, A Seymour, KW Kinzler, ... Science 256 (5058), 827-830, 1992 | 1291 | 1992 |
| Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes H Masuda, KA Baggerly, Y Wang, Y Zhang, AM Gonzalez-Angulo, ... Clinical cancer research 19 (19), 5533-5540, 2013 | 877 | 2013 |
| TGF-β1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains JA Pietenpol, RW Stein, E Moran, P Yaciuk, R Schlegel, RM Lyons, ... Cell 61 (5), 777-785, 1990 | 752 | 1990 |
| Cell cycle checkpoint signaling:: Cell cycle arrest versus apoptosis JA Pietenpol, ZA Stewart toxicology 181, 475-481, 2002 | 699 | 2002 |
| Sequence-specific transcriptional activation is essential for growth suppression by p53. JA Pietenpol, T Tokino, S Thiagalingam, WS El-Deiry, KW Kinzler, ... Proceedings of the National Academy of Sciences 91 (6), 1998-2002, 1994 | 581 | 1994 |
| Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes BD Lehmann, JA Pietenpol The Journal of pathology 232 (2), 142-150, 2014 | 572 | 2014 |
| Transforming growth factor beta 1 suppression of c-myc gene transcription: role in inhibition of keratinocyte proliferation. JA Pietenpol, JT Holt, RW Stein, HL Moses Proceedings of the National Academy of Sciences 87 (10), 3758-3762, 1990 | 572 | 1990 |
| Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets JM Balko, JM Giltnane, K Wang, LJ Schwarz, CD Young, RS Cook, ... Cancer discovery 4 (2), 232-245, 2014 | 568 | 2014 |
| A tale of two proteins: Differential roles and regulation of Smad2 and Smad3 in TGF‐β signaling KA Brown, JA Pietenpol, HL Moses Journal of cellular biochemistry 101 (1), 9-33, 2007 | 471 | 2007 |
| Cell-cycle dysregulation and anticancer therapy ZA Stewart, MD Westfall, JA Pietenpol Trends in pharmacological sciences 24 (3), 139-145, 2003 | 468 | 2003 |
| The ΔNp63α phosphoprotein binds the p21 and 14-3-3σ promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations MD Westfall, DJ Mays, JC Sniezek, JA Pietenpol Molecular and cellular biology 23 (7), 2264-2276, 2003 | 437 | 2003 |
| Significance of p63 amplification and overexpression in lung cancer development and prognosis PP Massion, PM Taflan, SM Jamshedur Rahman, P Yildiz, Y Shyr, ... Cancer research 63 (21), 7113-7121, 2003 | 429 | 2003 |
| Subtyping of triple‐negative breast cancer: implications for therapy VG Abramson, BD Lehmann, TJ Ballinger, JA Pietenpol Cancer 121 (1), 8-16, 2015 | 426 | 2015 |
| PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors BD Lehmann, JA Bauer, JM Schafer, CS Pendleton, L Tang, KC Johnson, ... Breast Cancer Research 16, 1-14, 2014 | 383 | 2014 |
